Biotech firm CSL Behring has announced the four-year results from the pivotal HOPE-B study confirming the long-term ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Netherlands-based Bilthoven Biologicals, the Dutch subsidiary of the Serum Institute of India and a leading end-to-end ...

Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...

The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and ...

Shares of rare disease drug developer X4 Pharmaceuticals took a battering after it said it will restructure its workforce and ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

China has issued a guideline on comprehensively deepening the reform of regulation of drugs and medical devices to promote the high-quality development of the pharmaceutical industry, the National ...

Trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has accused one of the country’s largest compounders, Hims & Hers, of running a misleading multi-million dollar Super Bowl ...

Klaus Edvardsen has been named chief medical officer (CMO) of Epitopea, an Anglo-Canadian company developing off-the-shelf RNA-based immunotherapies.

Karen Andersen, equity strategist at Morningstar, has issued an analysis of US pharma major Eli Lilly’s latest financial results, which were published yesterday.